In search of a selective therapy of viral infections

Antiviral Research

Volumn 85, Issue 1, 2010, Pages 19-24

  De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Interferon; Acyclovir; BVDU; Double stranded RNA; NNRTIs; NRTIs; NtRTIs; Reverse transcriptase

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; 9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)ADENINE; ACICLOVIR; ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; AMANTADINE; AMPLIGEN; ANTIVIRUS AGENT; BETA INTERFERON; BRIVIRAC; CIDOFOVIR; DOUBLE STRANDED RNA; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; IDOXURIDINE; INTERFERON; POLYINOSINIC POLYCYTIDYLIC ACID; RIBAVIRIN; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SMALL INTERFERING RNA; STAVUDINE; SURAMIN; TENOFOVIR; TENOFOVIR DISOPROXIL; TRIFLURIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; VIDARABINE; ZERPEX; ZIDOVUDINE; ZOSTEX;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CHRONIC FATIGUE SYNDROME; CYTOMEGALOVIRUS; DNA VIRUS; DRUG RESEARCH; DRUG SELECTIVITY; FLAVIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA; INFLUENZA VIRUS; MOLECULAR CLONING; MULTIPLE SCLEROSIS; NONHUMAN; PICORNAVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RETINITIS; REVIEW; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTIVIRAL AGENTS; HUMANS; INTERFERON-BETA; RNA, DOUBLE-STRANDED; RNA-DIRECTED DNA POLYMERASE; VIRUS DISEASES;

DNA VIRUSES; HEPATITIS B VIRUS; HERPESVIRIDAE; HUMAN HERPESVIRUS 3; SIMPLEXVIRUS;

EID: 73549106544     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.10.005     Document Type: Review

References (71)

1. Andrei G., Sienaert R., McGuigan C., De Clercq E., Balzarini J., and Snoeck R. Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides. Antimicrob. Agents Chemother. 49 (2005) 1081-1086
2. Baba M., Pauwels R., Herdewijn P., De Clercq E., Desmyter J., and Vandeputte M. Both 2′,3′-dideoxythymidine and its 2′,3′-unsaturated derivative (2′,3′-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochem. Biophys. Res. Commun. 142 (1987) 128-134
3. Baba M., Pauwels R., Balzarini J., Arnout J., Desmyter J., and De Clercq E. Mechanism of inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 6132-6136
4. Baltimore D. RNA-dependent DNA polymerase in virions of RNA tumour viruses. Nature 226 (1970) 1209-1211
5. Balzarini J., Holý A., Jindrich J., Naesens L., Snoeck R., Schols D., and De Clercq E. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob. Agents Chemother. 37 (1993) 332-338
6. Barré-Sinoussi F., Chermann J.C., Rey F., Nugeyre M.T., Chamaret S., Gruest J., Dauguet C., Axler-Blin C., Vézinet-Brun F., Rouzioux C., Rozenbaum W., and Montagnier L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220 (1983) 868-871
7. Broder S., Yarchoan R., Collins J.M., Lane H.C., Markham P.D., Klecker R.W., Redfield R.R., Mitsuya H., Hoth D.F., and Gelmann E. Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo. Lancet 2 (1985) 627-630
8. Carter W.A., and De Clercq E. Viral infection and host defense (many aspects of viral infection and recovery can be explained by the modulatory role of double-stranded RNA). Science 186 (1974) 1172-1178
9. Colla L., De Clercq E., Busson R., and Vanderhaeghe H. Synthesis and antiviral activity of water-soluble esters of acyclovir [9-(2-hydroxyethoxymethyl)guanine]. J. Med. Chem. 26 (1983) 602-604
10. Content J., De Wit L., Piérard D., Derynck R., De Clercq E., and Fiers W. Secretory proteins induced in human fibroblasts under conditions used for the production of interferon β. Proc. Nat. Acad. Sci. U.S.A. 79 (1982) 2768-2772
11. De Clercq E. Synthetic interferon inducers. Fortschritte der chemischen Forschung. In: Boschke F. (Ed). Topics in Current Chemistry vol. 52 (1974), Springer-Verlag, Berlin/Heidelberg/New York 173-208
12. De Clercq E. Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses. Cancer Lett. 8 (1979) 9-22
13. De Clercq E. Suramin in the treatment of AIDS: mechanism of action. Antiviral Res. 7 (1987) 1-10
14. De Clercq E. Highly potent and selective inhibition of varicella-zoster virus replication by bicyclic furo[2,3-d]pyrimidine nucleoside analogues. Med. Res. Rev. 23 (2003) 253-274
15. De Clercq E. The bicyclam AMD3100 story. Nat. Rev. Drug Discov. 2 (2003) 581-587
16. De Clercq E. Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster. Biochem. Pharmacol. 68 (2004) 2301-2315
17. De Clercq E. From adefovir to Atripla™ via tenofovir, Viread™ and Truvada™. Future Virol. 1 (2006) 709-715
18. De Clercq E. Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge. Biochem. Pharmacol. 73 (2007) 911-922
19. De Clercq E. The acyclic nucleoside phosphonates from their inception to clinical use: historical perspective. Antiviral Res. 75 (2007) 1-13
20. De Clercq E. The discovery of antiviral agents: ten different compounds, ten different stories. Med. Res. Rev. 28 (2008) 929-953
21. De Clercq E. Antiviral drug discovery: ten more compounds, and ten more stories (part B). Med. Res. Rev. 29 (2009) 571-610
22. De Clercq E. Another ten stories in antiviral drug discovery (part C): "old" and "new" antivirals, strategies, and perspectives. Med. Res. Rev. 29 (2009) 611-645
23. De Clercq, E., in press. Ten stories on antiviral drug discovery (part D): paradigms, paradoxes and paraductions. Med. Res. Rev.
24. De Clercq E. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem. Pharmacol. 77 (2009) 1655-1664
25. De Clercq E., and De Somer P. Antiviral activity of polyribocytidylic acid in cells primed with polyriboinosinic acid. Science 173 (1971) 260-262
26. De Clercq E., and Holý A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat. Rev. Drug Discov. 4 (2005) 928-940
27. De Clercq E., Descamps J., De Somer P., and Holý A. (S)-9-(2,3-Dihydroxypropyl)adenine: an aliphatic nucleoside analog with broad spectrum antiviral activity. Science 200 (1978) 563-565
28. De Clercq E., Descamps J., De Somer P., Barr P.J., Jones A.S., and Walker R.T. E-5-(2-Bromovinyl)-2′-deoxyuridine: a potent and selective antiherpes agent. Proc. Natl. Acad. Sci. U.S.A. 76 (1979) 2947-2951
29. De Clercq E., Balzarini J., Descamps J., and Eckstein F. Antiviral, antimetabolic and antineoplastic activities of 2′- or 3′-amino- or azido-substituted deoxyribonucleosides. Biochem. Pharmacol. 29 (1980) 1849-1851
30. De Clercq E., Degreef H., Wildiers J., de Jonge G., Drochmans A., Descamps J., and De Somer P. Oral (E)-5-(2-bromovinyl)-2′-deoxyuridine in severe herpes zoster. Br. Med. J. 281 (1980) 1178
31. De Clercq E., Holý A., Rosenberg I., Sakuma T., Balzarini J., and Maudgal P.C. A novel selective broad-spectrum anti-DNA virus agent. Nature 323 (1986) 464-467
32. De Clercq E., Sakuma T., Baba M., Pauwels R., Balzarini J., Rosenberg I., and Holý A. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res. 8 (1987) 261-272
33. De Clercq E., Yamamoto N., Pauwels R., Baba M., Schols D., Nakashima H., Balzarini J., Debyser Z., Murrer B.A., Schwartz D., Thornton D., Bridger G., Fricker S., Henson G., Abrams M., and Picker D. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 5286-5290
34. Derynck R., Content J., De Clercq E., Volckaert G., Tavernier J., Devos R., and Fiers W. Isolation and structure of a human fibroblast interferon gene. Nature 285 (1980) 542-547
35. Derynck R., Remaut E., Saman E., Stanssens P., De Clercq E., Content J., and Fiers W. Expression of the human fibroblast interferon gene in Escherichia coli. Nature 287 (1980) 193-197
36. Donzella G.A., Schols D., Lin S.W., Esté J.A., Nagashima K.A., Maddon P.J., Allaway G.P., Sakmar T.P., Henson G., De Clercq E., and Moore J.P. AMD3100, a small-molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med. 4 (1998) 72-77
37. Elion G.B., Furman P.A., Fyfe J.A., de Miranda P., Beauchamp L., and Schaeffer H.J. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc. Natl. Acad. Sci. U.S.A. 74 (1977) 5716-5720
38. Field A.K., Lampson G.P., Tytell A.A., and Hilleman M.R. Inducers of interferon and host resistance, IV. Double-stranded replicative form RNA (MS2-Ff-RNA) from E. coli infected with MS2 coliphage. Proc. Natl. Acad. Sci. U.S.A. 58 (1967) 2102-2108
39. Field A.K., Tytell A.A., Lampson G.P., and Hilleman M.R. Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes. Proc. Natl. Acad. Sci. U.S.A. 58 (1967) 1004-1010
40. Garcia-Lerma J.G., Otten R.A., Qari S.H., Jackson E., Cong M.E., Masciotra S., Luo W., Kim C., Adams D.R., Monsour M., Lipscomb J., Johnson J.A., Delinsky D., Schinazi R.F., Janssen R., Folks T.M., and Heneine W. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med. 5 (2008) e28
41. Isaacs A., and Lindenmann J. Virus interference. I. Interferon. Proc. R. Soc. Lond. 147 (1957) 258-267
42. Lampson G.P., Tytell A.A., Field A.K., Nemes M.M., and Hilleman M.R. Inducers of interferon and host resistance. I. Double-stranded RNA from extracts of Penicillium funiculosum. Proc. Natl. Acad. Sci. U.S.A. 58 (1967) 782-789
43. Leyssen P., Drosten C., Paning M., Charlier N., Paeshuyse J., De Clercq E., and Neyts J. Interferons, interferon inducers, and interferon-ribavirin in treatment of flavivirus-induced encephalitis in mice. Antimicrob. Agents Chemother. 47 (2003) 777-782
44. Lin T.S., Schinazi R.F., and Prusoff W.H. Potent and selective in vitro activity of 3′-deoxythymidin-2′-ene (3′-deoxy-2′,3′-didehydrothymidine) against human immunodeficiency virus. Biochem. Pharmacol. 36 (1987) 2713-2718
45. Lindenmann J. Interferon and before. J. Interferon Cytokine Res. 27 (2007) 2-5
46. Martin J.C., Hitchcock M.J.M., De Clercq E., and Prusoff W.H. Early nucleoside reverse transcriptase inhibitors for the treatment of HIV: a brief history of Stavudine (D4T) and its comparison with other dideoxynucleosides. Antiviral Res. 85 (2010) 34-38
47. Maudgal P.C., De Clercq E., Descamps J., Missotten L., De Somer P., Busson R., Vanderhaeghe H., Verhelst G., Walker R.T., and Jones A.S. (E)-5-(2-Bromovinyl)-2′-deoxyuridine in the treatment of experimental herpes simplex keratitis. Antimicrob. Agents Chemother. 17 (1980) 8-12
48. Maudgal P.C., Missotten L., De Clercq E., and Descamps J. Varicella-zoster virus in the human corneal endothelium: a case report. Bull. Soc. Belge Ophtalmol. 190 (1980) 71-86
49. Maudgal P.C., Dralands L., Lamberts L., De Clercq E., Descamps J., and Missotten L. Preliminary results of oral BVDU treatment of herpes zoster ophthalmicus. Bull. Soc. Belge Ophtalmol. 193 (1981) 49-56
50. Maudgal P.C., Missotten L., De Clercq E., Descamps J., and De Meuter E. Efficacy of (E)-5-(2-bromovinyl)-2′-deoxyuridine in the topical treatment of herpes simplex keratitis. Albrecht von Graefes Arch. Klin. Ophthalmol. 216 (1981) 261-268
51. McGuigan C., Barucki H., Blewett S., Carangio A., Erichsen J.T., Andrei G., Snoeck R., De Clercq E., and Balzarini J. Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain. J. Med. Chem. 43 (2000) 4993-4997
52. Mello C.C., and Conte Jr. D. Revealing the world of RNA interference. Nature 431 (2004) 338-342
53. Mitsuya H., and Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 1911-1915
54. Mitsuya H., Popovic M., Yarchoan R., Matsushita S., Gallo R.C., and Broder S. Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science 226 (1984) 172-174
55. Mitsuya H., Weinhold K.J., Furman P.A., St. Clair M.H., Lehrman S.N., Gallo R.C., Bolognesi D., Barry D.W., and Broder S. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. U.S.A. 82 (1985) 7096-7100
56. Mitsuya H., Looney D.J., Kuno S., Ueno R., Wong-Staal F., and Broder S. Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science 240 (1988) 646-649
57. 12U)] markedly protects mice against Coxsackie B3 virus-induced myocarditis. Antimicrob. Agents Chemother. 48 (2004) 267-274
58. Popovic M., Sarin P.S., Robert-Gurroff M., Kalyanaraman V.S., Mann D., Minowada J., and Gallo R.C. Isolation and transmission of human retrovirus (human T-cell leukemia virus). Science 219 (1983) 856-859
59. Schaeffer H.J., Beauchamp L., de Miranda P., Elion G.B., Bauer D.J., and Collins P. 9-(2-Hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature 272 (1978) 583-585
60. + cells. J. Acquir. Immune Defic. Syndr. 2 (1989) 10-15
61. Schols D., Esté J.A., Henson G., and De Clercq E. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res. 35 (1997) 147-156
62. Schols D., Struyf S., Van Damme J., Esté J.A., Henson G., and De Clercq E. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J. Exp. Med. 186 (1997) 1383-1388
63. Snoeck R., Wellens W., Desloovere C., Van Ranst M., Naesens L., De Clercq E., and Feenstra L. Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine]. J. Med. Virol. 54 (1998) 219-225
64. Tan F.L., and Yin J.Q. RNAi, a new therapeutic strategy against viral infection. Cell Res. 14 (2004) 460-466
65. Temin H.M., and Mizutani S. RNA-dependent DNA polymerase in virions of Rous sarcoma virus. Nature 226 (1970) 1211-1213
66. Tsai C.-C., Follis K.E., Sabo A., Beck T.W., Grant R.F., Bischofberger N., Benveniste R.E., and Black R. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 270 (1995) 1197-1198
67. Tytell A.A., Lampson G.P., Field A.K., and Hilleman M.R. Inducers of interferon and host resistance. III. Double-stranded RNA from reovirus type 3 virions (reo 3-RNA). Proc. Natl. Acad. Sci. U.S.A. 58 (1967) 1719-1722
68. Van Aerschot A. Oligonucleotides as antivirals: dream or realistic perspective?. Antiviral Res. 71 (2006) 307-316
69. Van Cutsem E., Snoeck R., Van Ranst M., Fiten P., Opdenakker G., Geboes K., Janssens J., Rutgeerts P., Vantrappen G., and De Clercq E. Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine. J. Med. Virol. 45 (1995) 230-235
70. Whitley R.J., Ch'ien L.T., Dolin R., Galasso G.J., and Alford Jr. C.A. Adenine arabinoside therapy of herpes zoster in the immunosuppressed. NIAID collaborative antiviral study. N. Engl. J. Med. 294 (1976) 1193-1199
71. Willyard C. A preemptive strike against HIV. Nat. Med. 15 (2009) 126-129